<DOC>
	<DOCNO>NCT02001584</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability pharmacokinetics predefined dose range co-administered Baclofen Memantine non-obese ( Part A ) obese ( Part B ) , otherwise healthy subject .</brief_summary>
	<brief_title>A Study Examine , Safety , Tolerability Pharmacokinetics Co-Administered Baclofen Memantine Obese Lean , Otherwise Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Adult male female age 18 45 year inclusive ; 2 . Subjects body mass index : For Part A : ≥18 kg/m² ≤25 kg/m² ; For Part B : ≥33 kg/m² ≤40 kg/m² . 3 . Subjects total body weight ≥50 kg ( Part A Part B ) ; 4 . Subjects healthy determine Investigator base pre study medical history , physical examination , vital sign ( blood pressure , pulse rate , respiratory rate body temperature ) 12lead ECG screen admission ; 5 . Subjects whose clinical laboratory test result clinically relevant acceptable Investigator screen admission ; 6 . Aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase bilirubin ≤1.5 x upper limit normal ( ULN ) ; 7 . Subjects negative hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) I II test screen ; 8 . Subjects negative drug abuse alcohol test screen admission ; 9 . Subjects nonsmoker smoke use nicotinecontaining product least 3 month prior screen ; 10 . Subjects estimate creatinine clearance ≥100 mL/minute male subject ≥90 mL/minute female subject ( CockcroftGault method ) screening ; 11 . Subjects able willing give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>